Addiction

Long-acting buprenorphine depot injections may be efficacious in treatment of opioid use disorder

Weekly or monthly buprenorphine depot injections were non-inferior to daily sublingual buprenorphine/naloxone in maintaining no evidence of illicit opioid use at 24 weeks in outpatients with opioid use disorder.

Unit-dose packaging of buprenorphine-naloxone associated with reduced pediatric unintentional exposures

Pediatric unintentional opioid exposures decreased by more than 75% following the introduction of child-resistant unit-dose packaging.

Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes

Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes

By

Patients who use medical marijuana may be more likely to use prescription drugs for both medical and nonmedical purposes.

First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms

First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms

By

Lucemyra, a selective alpha 2-adrenergic receptor agonist, works by reducing the release of norepinephrine and decreasing sympathetic tone.

Opioid-Related Payments Linked to Increase in Opioid Rx

Opioid-Related Payments Linked to Increase in Opioid Rx

Receipt of opioid-related payments from industry in 2014 was associated with increased opioid prescribing in 2015.

Efficacy of Prazosin in Treating Alcohol Use Disorder

Efficacy of Prazosin in Treating Alcohol Use Disorder

By

Participants in the prazosin group were more likely to experience dizziness on standing.

Lofexidine Effective for Opioid Withdrawal Symptoms

Lofexidine Effective for Opioid Withdrawal Symptoms

By

Investigators pooled data from 2 phase 3 placebo-controlled studies to evaluate the safety and efficacy of lofexidine for opioid withdrawal symptoms.

Sources of Misused Opioids in Older Adults

Sources of Misused Opioids in Older Adults

By

Recent physician-prescribed opioids represent the main source of provenance of the drug in individuals age ≥65 years who misuse them.

Contribution of Synthetic Opioids to Drug Overdose Deaths

Contribution of Synthetic Opioids to Drug Overdose Deaths

By

Opioids were the leading contributor to drug overdose deaths between 2015 and 2016.

Motivations of Stimulant Misuse in Adults in the United States

Motivations of Stimulant Misuse in Adults in the United States

By

Investigators examined the prevalence of prescription stimulant use, misuse, use disorder, and motivations for misuse in adults in the US from 2015 to 2016.

Substance Use Disorders Associated With Conversion From Schizotypal Disorder to Schizophrenia

Substance Use Disorders Associated With Conversion From Schizotypal Disorder to Schizophrenia

By

These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.

Smoking Cessation Pharmacotherapies May Not Increase MACE

Smoking Cessation Pharmacotherapies May Not Increase MACE

By

There were no observable differences in the incidence of any cardiovascular events across the smoking cessation treatment groups.

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

By

The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.

Knowledge Not Tied to Addictive Tanning Behavior in Millennials

Knowledge Not Tied to Addictive Tanning Behavior in Millennials

For millennials, sun protection knowledge is not associated with addictive tanning behavior.

Intranasal Esketamine Rapidly Improves Symptoms of Depression and Suicidality

Intranasal Esketamine Rapidly Improves Symptoms of Depression and Suicidality

By

Although there were no indications of esketamine dependence, misuse, diversion, or withdrawal symptoms in this trial, this is a possible concern, and the authors call for further evidence from clinical trials to evaluate the drug's potential for abuse.

April 28 Is Drug Take Back Day

April 28 Is Drug Take Back Day

By

April 28, 2018 is National Prescription Drug Take Back Day.

Questions Surround Concept of Internet Gaming Disorder

Questions Surround Concept of Internet Gaming Disorder

The concept of internet gaming disorder and the pathways leading to it are unclear.

Prenatal Exposure to Opiates, Illicit Substances Associated With ADHD, Autism in Offspring

Prenatal Exposure to Opiates, Illicit Substances Associated With ADHD, Autism in Offspring

By

The results of this study suggest that children prenatally exposed to substances should receive early mental health assessment.

Predicting Suicidal Ideation in Veterans With Chronic Pain

Predicting Suicidal Ideation in Veterans With Chronic Pain

By

A number of factors including chronic pain co-occurring with posttraumatic stress disorder and pain interference may predict suicidal ideation and violent impulses in US veterans with chronic pain.

How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics

How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics

By

Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.

Talk therapy, modified for literacy level, helps ease chronic pain for disadvantaged populations

Both modified cognitive behavioral therapy (CBT) and pain education (EDU) interventions were associated with improved pain in patients with disadvantaged backgrounds.

Significant variation in mortality trends in substance use disorders among US counties

Mortality rates decreased for alcohol use disorders, self-harm, and interpersonal violence between 1980 and 2014. Mortality rates for drug use disorders increased both nationally and in each county over the same period.

Little Packaging Information on Storage, Disposal of Opioid Pain-Relievers

Little Packaging Information on Storage, Disposal of Opioid Pain-Relievers

By

Package inserts of opioid analgesics may not consistently provide information regarding safe drug storage and/or disposal.

Treatment Duration of Extended-Release Naltrexone for Opioid Dependence and Outcomes

Treatment Duration of Extended-Release Naltrexone for Opioid Dependence and Outcomes

By

A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.

Interventions in Middle School Can Reduce Alcohol Misuse in Mexican American Adolescents

Interventions in Middle School Can Reduce Alcohol Misuse in Mexican American Adolescents

By

Because even moderate reductions in adolescent drinking and alcohol use disorders have the potential to reduce short- and long-term public health harms, these findings support broad implementation of the program.

Antisocial and Borderline Personality Disorders Associated With Cannabis Use

Antisocial and Borderline Personality Disorders Associated With Cannabis Use

By

The investigators found that antisocial (β=0.23) and borderline (β=0.20) personality disorders were strongly associated with cannabis use as well as with cannabis use disorder.

Increased Odds of Cigarette Use, Relapse Among Cannabis Users

Increased Odds of Cigarette Use, Relapse Among Cannabis Users

By

The findings of these analyses suggest that, to an extent, this relationship might be generalized to cannabis users as a whole, not just those diagnosed with a cannabis use disorder.

Liquids in E-Cigarettes Are Heterogeneous, Frequently Toxic

Liquids in E-Cigarettes Are Heterogeneous, Frequently Toxic

The more chemicals in e-liquid, the more toxic it is likely to be.

Scale of Online Marketplace for Marijuana Increasing

Scale of Online Marketplace for Marijuana Increasing

Online marijuana searches grew by 98 percent as a proportion of all searches from 2005 to 2017.

Lofexidine Gets FDA Committee Nod for Opioid Withdrawal

Lofexidine Gets FDA Committee Nod for Opioid Withdrawal

By

If approved, Lucemyra will be the first non-opioid medication indicated to mitigate opioid withdrawal symptoms.

Sign Up for Free e-newsletters